Form 4: IN8BIO Director Emily Fairbairn Acquires Stock Options

Director Emily Fairbairn acquired stock options in IN8BIO, INC. on December 19, 2024.

Summary

• On December 19, 2024, Emily Fairbairn, a director of IN8BIO, INC., acquired stock options.
• The stock options grant the right to buy 31,559 shares of common stock at an exercise price of $0.24 per share.
• The options vest on December 19, 2025, contingent upon continued service.
• Following the transaction, Fairbairn directly owns 31,559 derivative securities.

Sentiment

Score: 7

Explanation: The granting of stock options is generally a positive sign, indicating confidence in the company's future. However, it also represents potential future dilution for existing shareholders.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• The vesting schedule of one year is fairly standard.
• The exercise price is $0.24 per share.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised.
• Employees may be motivated by the director's acquisition of stock options.

Key Dates